骨保护素与糖尿病性骨质疏松的研究进展  

The investigation advancement of the relationship between osteopro-tegerin and diabetic osteoporosis

作　　者：朱明明[1] 梁玮[1] 王微[1] 

机构地区：[1]哈尔滨医科大学第二临床医学院内分泌科,哈尔滨150086

出　　处：《中国骨质疏松杂志》2008年第11期814-817,共4页Chinese Journal of Osteoporosis

摘　　要：骨保护素(Osteoprotegerin,OPG)是肿瘤坏死因子受体超家族成员,是骨代谢的一个重要调节因子,具有抑制破骨细胞分化,抑制其骨吸收活性及其凋亡的作用。随糖尿病(Diabetes mellitus,DM)患病率的逐年增加,糖尿病骨质疏松的患病率也明显增高,并成为DM患者致死、致残的重要原因,严重影响患者的生活质量,给患者家庭和社会都带来沉重的经济负担。近年来,糖尿病与骨质疏松的关系备受关注,通过对OPG的深入研究,可能为糖尿病骨质疏松的防治提供依据,对指导临床监测、治疗糖尿病骨质疏松具有重要价值。Osteoprotegerin （OPG）, a member of the tumor necrosis factor （TNF） receptor family, has been identified as a regulator of bone resorption, and has effects in inhibiting osteoclast differentiation as well as its activity of bone resorption and apoptosis. With the increase of DM morbidity ,the morbidity of Diabetic Osteoporosis （DO） is dramatically increasing, and has become an important cause of diabetic patients＇mutilation and death, seriously affects living quality of diabetic patients, and adds heavy economic burden to family and society. In the past few years, with the increase of DO, the relationship between Diabetes mellitus and Osteoporosis has been paid close attention to. Through the study and research in OPG, evidence of prevention and cure of DO could be provided. And it probably shows instructive value of monitoring therapy of osteoporosis in clinic.

关 键 词：骨保护素 骨质疏松 骨密度 糖尿病 糖尿病微血管并发症 

分 类 号：R58[医药卫生—内分泌]